
Soficitinib (Compound 20) is a селективный ингибитор targeting tyrosine киназы 2 (TYK2) and Janus киназы 2 (JAK2) with an IC50 values of 0.5 nM and 1.2 nM, respectively. Soficitinib is promising for research of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis) and inflammatory diseases.
Soficitinib (Compound 20) is a selective inhibitor targeting tyrosine kinase 2 (TYK2) and Janus kinase 2 (JAK2) with an IC50 values of 0.5 nM and 1.2 nM, respectively. Soficitinib is promising for research of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis) and inflammatory diseases.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.